UA88773C2 - Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря - Google Patents

Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря

Info

Publication number
UA88773C2
UA88773C2 UAA200603708A UAA200603708A UA88773C2 UA 88773 C2 UA88773 C2 UA 88773C2 UA A200603708 A UAA200603708 A UA A200603708A UA A200603708 A UAA200603708 A UA A200603708A UA 88773 C2 UA88773 C2 UA 88773C2
Authority
UA
Ukraine
Prior art keywords
bladder
treatment
irritation
hyperactive
bladder irritation
Prior art date
Application number
UAA200603708A
Other languages
English (en)
Ukrainian (uk)
Inventor
Крейг П. Смит
Мишель П. Ретбоун
Маргарет Петти
Девид Ремп
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of UA88773C2 publication Critical patent/UA88773C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к N-(пиридинил)-1Н-индол-1-аминам формулы I, которые имеют уникальную комбинацию блокирующих свойств как в отношении калиевых,, так и в отношении натриевых каналов. Указанные соединения полезны для лечения раздражения и дисфункции мочевого пузыря.
UAA200603708A 2001-02-15 2006-04-04 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря UA88773C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
UA88773C2 true UA88773C2 (ru) 2009-11-25

Family

ID=23024747

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2003098376A UA80394C2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases
UAA200603708A UA88773C2 (ru) 2001-02-15 2006-04-04 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA2003098376A UA80394C2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases

Country Status (39)

Country Link
US (10) US6967210B2 (ru)
EP (1) EP1368031A2 (ru)
JP (3) JP2004518711A (ru)
KR (3) KR100951542B1 (ru)
CN (2) CN1529598A (ru)
AP (1) AP1749A (ru)
AR (1) AR035750A1 (ru)
AU (3) AU2002247200B9 (ru)
BR (1) BR0207272A (ru)
CA (1) CA2438712A1 (ru)
CO (1) CO5390085A1 (ru)
CR (1) CR7023A (ru)
CZ (1) CZ20032172A3 (ru)
EA (2) EA012409B1 (ru)
EC (1) ECSP024218A (ru)
EE (1) EE200300363A (ru)
GB (1) GB0119435D0 (ru)
HK (1) HK1080361B (ru)
HR (1) HRP20030652A2 (ru)
HU (1) HUP0303203A3 (ru)
IL (2) IL157341A0 (ru)
MA (1) MA26152A1 (ru)
ME (1) MEP21208A (ru)
MX (1) MXPA03006110A (ru)
MY (1) MY157745A (ru)
NO (1) NO20033622L (ru)
NZ (4) NZ556697A (ru)
OA (1) OA12549A (ru)
PA (1) PA8540101A1 (ru)
PE (1) PE20040175A1 (ru)
PL (1) PL363638A1 (ru)
SG (1) SG134170A1 (ru)
SK (1) SK10392003A3 (ru)
TR (4) TR200800691T2 (ru)
TW (1) TWI325319B (ru)
UA (2) UA80394C2 (ru)
WO (1) WO2002064126A2 (ru)
YU (1) YU62903A (ru)
ZA (1) ZA200306124B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
WO2011118364A1 (en) * 2010-03-26 2011-09-29 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
CA2825810A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of 4-aminopyridine to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3727587A4 (en) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (en) 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE69016531T2 (de) * 1989-08-02 1995-07-06 Hoechst Roussel Pharma 2,3-Dihydro-1-(pyridinylamino)-indole, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
US6544976B1 (en) * 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
US20090281147A1 (en) 2009-11-12
TR200301330T2 (tr) 2004-12-21
TR200800693T2 (tr) 2008-07-21
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
ZA200306124B (en) 2004-11-08
WO2002064126A2 (en) 2002-08-22
EP1368031A2 (en) 2003-12-10
AR035750A1 (es) 2004-07-07
US6967210B2 (en) 2005-11-22
AU2002247200B9 (en) 2008-07-10
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
CA2438712A1 (en) 2002-08-22
PL363638A1 (en) 2004-11-29
EA012409B1 (ru) 2009-10-30
US20090209594A1 (en) 2009-08-20
OA12549A (en) 2006-06-05
US20040157889A1 (en) 2004-08-12
US7179821B2 (en) 2007-02-20
EE200300363A (et) 2003-10-15
YU62903A (sh) 2006-05-25
NZ539159A (en) 2006-11-30
ECSP024218A (es) 2003-09-24
US7534803B2 (en) 2009-05-19
NO20033622L (no) 2003-10-06
UA80394C2 (en) 2007-09-25
MXPA03006110A (es) 2005-07-01
CR7023A (es) 2003-11-17
NZ556697A (en) 2009-01-31
SG134170A1 (en) 2007-08-29
AP2003002834A0 (en) 2003-09-30
MA26152A1 (fr) 2004-07-01
KR20040014459A (ko) 2004-02-14
KR20090005255A (ko) 2009-01-12
GB0119435D0 (en) 2001-10-03
AU2009238332A1 (en) 2009-12-10
IL157341A (en) 2010-11-30
KR20090005254A (ko) 2009-01-12
US7230015B2 (en) 2007-06-12
AP1749A (en) 2007-06-13
CO5390085A1 (es) 2004-04-30
KR100951540B1 (ko) 2010-04-09
NZ544720A (en) 2007-08-31
NZ527011A (en) 2005-07-29
PA8540101A1 (es) 2003-09-05
CN100522164C (zh) 2009-08-05
US20060025452A1 (en) 2006-02-02
CN1679564A (zh) 2005-10-12
HUP0303203A3 (en) 2007-11-28
WO2002064126A3 (en) 2003-02-20
CZ20032172A3 (cs) 2004-01-14
EA200300882A1 (ru) 2003-12-25
US20090270458A1 (en) 2009-10-29
MEP21208A (en) 2010-06-10
JP2004518711A (ja) 2004-06-24
HRP20030652A2 (en) 2005-06-30
AU2008201179B2 (en) 2009-08-20
JP2010120958A (ja) 2010-06-03
KR100951542B1 (ko) 2010-04-09
EA200600896A1 (ru) 2006-08-25
AU2002247200B2 (en) 2007-12-13
HUP0303203A2 (hu) 2003-12-29
NO20033622D0 (no) 2003-08-14
IL157341A0 (en) 2004-02-19
CN1529598A (zh) 2004-09-15
HK1080361A1 (zh) 2006-04-28
AU2008201179A1 (en) 2008-04-03
EA011319B1 (ru) 2009-02-27
US20030105150A1 (en) 2003-06-05
BR0207272A (pt) 2004-02-10
TR200800691T2 (tr) 2008-03-21
HK1080361B (zh) 2009-10-30
PE20040175A1 (es) 2004-03-29
US20040157888A1 (en) 2004-08-12
US20050159456A1 (en) 2005-07-21
US20090209595A1 (en) 2009-08-20
JP2009185045A (ja) 2009-08-20
US20050234105A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
DE60112974D1 (en) Carbolinderivate
DE60329001D1 (en) 8-hydroxychinolinderivate
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
MY135333A (en) Modulators of the glucocorticoid receptor
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
IL183514A0 (en) Pyrrolidine inhibitors of iap
AU3652102A (en) Compounds and their uses
DE60216233D1 (en) Carbolinderivate
WO2007106192A3 (en) Inhibitors of iap
AU3831301A (en) Method for treating ocular pain
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
NO20054494L (no) Peptidvektorer
MXPA04006041A (es) Antivirales de piridoquinoxalina.
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2005060693A3 (en) 9-desoxoerythromycin compounds as prokinetic agents
DE60329326D1 (de) Tace inhibitoren
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
PL1651596T3 (pl) Nowe pochodne 4,4’ - ditiobis(3-aminobutano-1-sulfonianów) i zawierające je kompozycje